English  |  正體中文  |  简体中文  |  Items with full text/Total items : 17482/19768 (88%)
Visitors : 6312054      Online Users : 270
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: http://ir.cnu.edu.tw/handle/310902800/28694


    標題: Serum vascular adhesion protein-1 predicts all-cause mortality and cancer-related mortality in subjects with colorectal cancer
    作者: Li, Yu-I
    Hung, Ji-Shiang
    Yu, Tse-Ya
    Liou, Jyh-Ming
    Wei, Jung-Nan
    Kao, Hsien-Li
    Chuang, Lee-Ming
    Shun, Chia-Tung
    Lee, Po-Huang
    Lai, Hong-Shiee
    Su, Chien-Yin
    Li, Hung-Yuan
    Liang, Jin-Tung
    貢獻者: 職業安全衛生系
    關鍵字: Vascular adhesion protein-1
    Semicarbazide-sensitive amine oxidase
    Primary amine oxidase
    Mortality
    Colorectal cancer
    日期: 2014-01
    上傳時間: 2015-05-06 21:25:25 (UTC+8)
    出版者: Elsevier Science Bv
    摘要: Background: Vascular adhesion protein-1 (VAP-1) participates in inflammation and catalyzes the breakdown of amines to produce aldehyde, hydrogen peroxide, and ammonia. Serum VAP-1 can predict cancer mortality, including colorectal cancer (CRC) mortality, in type 2 diabetic subjects. However, it remains unknown if serum VAP-1 can predict mortality in CRC patients. This prospective cohort study investigates if serum VAP-1 is a novel biomarker for mortality prediction in CRC. Methods: We enrolled 300 CRC patients. Preoperative serum VAP-1 was measured by time-resolved immunofluorometric assay. They were followed until September 2009 or death, which was ascertained by the National Death Registration System. Results: The median follow-up period was 4.7 years. Compared with normal counterpart, VAP-1 immunoactivity was upregulated in CRC tissues, especially at the invasion front. Serum VAP-1 can independently predict all-cause mortality (HR: 1.0026, 95% Cl: 1.0003-1.0050, P < 0.05) and cancer-related mortality (HR: 1.0026, 95% Cl: 1.0001-1.0050, P <0.05). A risk score composed of age, gender, carcinoembryonic antigen (CEA) >5 ng/ml, tumor grading, tumor staging, and serum VAP-1 could stratify CRC patients into low-, intermediate-, and high-risk subgroups, with a 5-year mortality rate of 10%, 34%, and 78%, respectively. Conclusions: Serum VAP-1 predicts mortality independently and improves risk stratification in CRC subjects. (C) 2013 Elsevier B.V. All rights reserved.
    關聯: Clinica Chimica Acta, v.428 n., pp.51-56
    Appears in Collections:[職業安全衛生系(含防災所)] 期刊論文

    Files in This Item:

    File Description SizeFormat
    index.html0KbHTML587View/Open


    All items in CNU IR are protected by copyright, with all rights reserved.


    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback